Knowledge Library

  Advancements in next-generation cell and gene therapies are fulfilling the promise of personalized medicine and attempting to cure and heal patients. Multiple approved products have been launched in global markets and the number of clinical trials continues to grow. Developing innovative advanced therapies is one of the biopharmaceutical industry’s greatest opportunities to dramatically improve …Read More >

WuXi Advanced Therapies Inc. (WuXi ATU) today announced the expansion of its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP Plasmid for use in a wide variety of R&D, clinical, and  commercial bioprocessing applications, with an integrated platform of capabilities that allows for a seamless single-source approach …Read More >

In order to promote the public’s awareness of rare diseases and showcase WuXi AppTec’s positive social impact, on Aug. 20, we organized a 3-session webinar series on Spinal Muscular Atrophy, including a fireside chat between Dr. David Chang, CEO of WuXi ATU, and Paulo Fontoura, Global Head and SVP, Neuroscience and Rare Diseases Clinical Development …Read More >

– The development of innovative advanced therapies represents a great opportunity to dramatically improve patients’ lives.  However, the rapid and efficient production of these advanced therapies remains a considerable challenge. – Recent technological advancements in the process development of CAR-T cell therapy manufacturing. – A modular approach was used to optimize unit operations to build …Read More >

WuXi Advanced Therapies has added Mycoplasma Real-Time PCR Detection (MycoSEQ™) to our menu of innovative solutions! This assay method can be used for lot release by drugmakers of biotherapeutics, cell therapy products, biologics, and vaccines to detects more than 90 mycoplasma species with high specificity and no cross-reactivity to closely-related bacterial species rapidly and reliably. …Read More >